NOT YET RECRUITING
NCT07671027
PIEZO-101 First-in-Human Safety and Proof-of-Concept Study
The aim of this first-in-human clinical study is to explore the safety, tolerability, pharmacodynamics, and exploratory efficacy of PIEZO-101, an investigational plasmid DNA biostimulator that aims to restore expression of key proteins in the skin for extracellular matrix rejuvenation. PIEZO-101 is administered using an intradermal injection followed by localized electroporation using the investigational device Piezopen. This clinical trial will study safety and tolerability, pharmacodynamics using biopsies from the left knee, and exploratory efficacy using photography on the décolleté. Up to 8 participants may be enrolled to ensure 6 evaluable participants complete the study.
Gender: FEMALE
Ages: 40 Years - 65 Years
Skin Aging
Wrinkles in Decolletage
Wrinkles in Left Knee
+2